威尚生物医药

Versantus is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of first-in-class and best-in-class small molecule drugs. The company focuses on targeting protein-protein interactions (PPI) and other difficult-to-drug targets, primarily in the field of oncology. Its lead candidate, V-024, is a highly potent and selective MDM2-p53 inhibitor designed to restore p53-mediated tumor suppression in various cancers. Beyond its lead program, Versantus is advancing a pipeline of inhibitors targeting the BCL-2 family of proteins to induce apoptosis in cancer cells. The company's approach combines structure-based drug design with a deep understanding of cancer biology to address significant unmet medical needs.